The Experts below are selected from a list of 13566 Experts worldwide ranked by ideXlab platform

Shaobing Zhou - One of the best experts on this subject based on the ideXlab platform.

  • bioinspired 3d multilayered shape memory scaffold with a hierarchically changeable micropatterned surface for efficient vascularization
    ACS Applied Materials & Interfaces, 2017
    Co-Authors: Dian Liu, Tao Xiang, Tao Gong, Tian Tian, Xian Liu, Shaobing Zhou
    Abstract:

    How to achieve three-dimensional (3D) cell alignment and subsequent prompt tissue regeneration remains a great challenge. Here, inspired by the interior 3D architecture of native arteries, we develop a New 3D multilayered shape memory vascular scaffold with a hierarchically changeable micropatterned surface for vascularization. The shape memory function renders the implantation of the scaffold safe and convenient via minimally invasive surgery. By co-culturing endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) on the 3D multilayered structure, the inner monolayer, which has a square micropatterned surface, can promote EC adhesion and migration, resulting in a rapid endothelialization, and the outer multilayers, which have rectangular micropatterned surfaces, can induce a circumferential alignment of VSMCs. After implantation in the cervical artery of a New Zealand Rabbit for 120 days, the graft developed a high capacity for modulating cellular 3D alignment, to generate a neonatal functional ...

  • Bioinspired 3D Multilayered Shape Memory Scaffold with a Hierarchically Changeable Micropatterned Surface for Efficient Vascularization
    2017
    Co-Authors: Dian Liu, Tao Xiang, Tao Gong, Tian Tian, Xian Liu, Shaobing Zhou
    Abstract:

    How to achieve three-dimensional (3D) cell alignment and subsequent prompt tissue regeneration remains a great challenge. Here, inspired by the interior 3D architecture of native arteries, we develop a New 3D multilayered shape memory vascular scaffold with a hierarchically changeable micropatterned surface for vascularization. The shape memory function renders the implantation of the scaffold safe and convenient via minimally invasive surgery. By co-culturing endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) on the 3D multilayered structure, the inner monolayer, which has a square micropatterned surface, can promote EC adhesion and migration, resulting in a rapid endothelialization, and the outer multilayers, which have rectangular micropatterned surfaces, can induce a circumferential alignment of VSMCs. After implantation in the cervical artery of a New Zealand Rabbit for 120 days, the graft developed a high capacity for modulating cellular 3D alignment, to generate a neonatal functional blood vessel with an endothelium layer in the inner layer and multilevel VSMC circumferential alignments in the outer layers

Y J Gordon - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand Rabbit ocular model
    Investigative Ophthalmology & Visual Science, 2000
    Co-Authors: Eric G Romanowski, Y J Gordon
    Abstract:

    (66%); P 5 0.000002], Ad5 [84/160 (53%) versus 131/152 (86%); P , 0.000001], and Ad6 [36/128 (28%) versus 82/128 (64%); P , 0.000001]: and reduced the duration of Ad shedding for Ad1 (4.9 6 1.9 versus 9.3 6 3.3 days; P , 0.00007), Ad5 (6.4 6 2.8 versus 11.5 6 2.3 days; P , 0.0001), and Ad6 (4.4 6 2.1 versus 8.4 6 2.5 days; P , 0.00004). CONCLUSIONS. Topical 0.5% cidofovir twice daily for 7 days demonstrated significant antiviral activity against multiple adenoviral serotypes (Ad1, Ad5, and Ad6) in the New Zealand Rabbit ocular model. These in vivo data expand in vitro studies indicating the efficacy of cidofovir against different adenovirus serotypes and support its use in clinical trials. (Invest Ophthalmol Vis Sci. 2000;41: 460 ‐ 463)

  • topical corticosteroids reverse the antiviral effect of topical cidofovir in the ad5 inoculated New Zealand Rabbit ocular model
    Investigative Ophthalmology & Visual Science, 1997
    Co-Authors: Eric G Romanowski, T Araullocruz, Y J Gordon
    Abstract:

    Purpose. To determine how the addition of topical corticosteroids would affect the anti-adenoviral inhibitory effect of topical cidofovir (S-HPMPC) in the Ad5 New Zealand (Ad5/NZ) Rabbit ocular model. Methods. In a series of experiments (two-eye design), Ad5-inoculated/NZ Rabbits (10 6 pfu/eye) were treated with 1 of 3 treatment regimens. Group I was administered 1% cidofovir (CDV) twice a day for 3 days plus comfort tears four times a day for 14 days. Group 2 was administered 1% CDV twice a day for 3 days plus 1% Pred Forte four times a day for 14 days. Group 3 was administered vehicle twice a day for 3 days plus comfort tears four times a day for 14 days and served as the control. All eyes were evaluated for 21 days for serial eye titers, Ad5 positive eyes, and duration of Ad5 shedding. Results. Compared to control eyes in the Ad5/NZ Rabbit ocular model, CDV alone demonstrated a significant antiviral inhibitory effect: reduced mean Ad5 eye titer during the early phase of infection (days 3 to 7), fewer Ad5-positive eyes during the early and late (days 9 to 21) phases of infection, and shortened duration of shedding. However, concomitant treatment with both Pred Forte and CDV significantly reversed the antiviral inhibitory activity of CDV: increased mean Ad5 eye titer, increased Ad5-positive eyes (early and late phases) and prolonged duration of shedding. Conclusions. These experimental data further support the clinical development of cidofovir as a topical antiviral agent, but they' do not support a treatment regimen that includes a combination of topical corticosteroids and topical cidofovir as a desirable strategy for the treatment of symptomatic adenoviral ocular infection.

  • hpmpc a broad spectrum topical antiviral agent inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand Rabbit ocular model
    Cornea, 1994
    Co-Authors: Y J Gordon, Eric G Romanowski, T Araullocruz
    Abstract:

    Previously, we demonstrated that HPMPC, a New, broad-spectrum antiviral agent, inhibited adenovirus type 5 in the New Zealand (NZ) Rabbit ocular model (Cornea 1992; 11:529-33). Historically, no antiviral agent has been demonstrated to be effective against both herpes simplex virus type 1 (HSV-1) and adenovirus eye infections in an experimental animal model. In this study, we compared topical 0.2% HPMPC to 1% trifluridine and vehicle control in the NZ Rabbit HSV-1 keratitis model. Using a double-masked, two-eye design, NZ Rabbits were inoculated in both eyes with HSV-1 W strain (10(5) pfu/eye), and dendritic keratitis and HSV-1 ocular titers were measured serially. Compared with the control group, both topical 0.2% HPMPC and 1% trifluridine significantly reduced healing time of HSV-1 dendritic keratitis, lowered HSV-1 ocular titers on days 3 through 11, and shortened duration of HSV-1 shedding in the tear film. For all outcome parameters measured, topical 0.2% HPMPC was as effective as 1% trifluridine. A New concept of a broad-spectrum topical antiviral agent was shown to be effective against HSV-1 in an NZ Rabbit keratitis model, and further development toward clinical application appears desirable.

  • topical hpmpc inhibits adenovirus type 5 in the New Zealand Rabbit ocular replication model
    Investigative Ophthalmology & Visual Science, 1994
    Co-Authors: Y J Gordon, Eric G Romanowski, T Araullocruz
    Abstract:

    Purpose. To evaluate the antiviral inhibitory activity of HPMPC against ocular adenoviral serotypes in vitro and to determine the therapeutic efficacy and ocular toxicity of treatment with topical HPMPC on established adenovirus type 5 (AD5) McEwen infection in the New Zealand (NZ) Rabbit ocular replication model. Methods. The 50% inhibitory dose (ID50) of HPMPC was determined for various clinical isolates of AD5 and AD8 by plaque assay in A549 cells. In vivo inhibitory effects were measured by serial ocular titers and duration of viral shedding in the AD5-NZ Rabbit ocular model. Local ocular toxicity was evaluated by external and slit lamp examination for blepharitis, conjunctivitis, keratitis, and iritis. Results. The mean IDS() for seven isolates of AD8 was 0.47 (range, 0.02 //g/ml to 0.82 /ig/ml), and the mean IDS0 for seven isolates of AD5 was 1.03 (range, 0.15 ^g/ml to 2.80 /^g/ml). In a series of in vivo experiments, topical administration of HPMPC for as long as 10 days (total dose, >2.8 mg) significantly reduced both AD5 ocular titers and the number of days of viral shedding compared to that for vehicle-treated control eyes. Local ocular toxicity was not clinically significant at a total dose of <10 mg administered for as long as 10 days. Conclusions. HPMPC, a broad-spectrum, long-acting nucleoside monophosphate analog, is a promising candidate for the treatment of epidemic keratoconjunctivitis infections. Further studies to ensure safety and efficacy in humans are warranted. Invest Ophthalmol Vis Sci. 1994;35:4135-4143.

  • pretreatment with topical 0 1 s 1 3 hydroxy 2 phosphonylmethoxypropyl cytosine inhibits adenovirus type 5 replication in the New Zealand Rabbit ocular model
    Cornea, 1992
    Co-Authors: Y J Gordon, Eric G Romanowski, T Araullocruz, E De Clercq
    Abstract:

    Currently there is no clinically effective antiviral agent for the prevention or treatment of ocular adenoviral infections. Using a paired-eye, masked design, we tested the antiviral efficacy of topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in the New Zealand Rabbit ocular model after topical and intrastromal inoculation with 100 microliters (4 x 10(5) plaque-forming units per eye) of adenovirus type 5 McEwen, a clinical isolate. Prevention studies involved pretreatment (six times a day) 1 day before inoculation and continuing for 4 additional days. Compared with the control eyes, the pretreated eyes showed a significant reduction in the peak viral eye titers on days 3, 4, 5, and 7 after treatment (p < 0.03-0.005), and a reduction in the duration of viral sheeding (p < 0.02). Rebound increase in adenoviral titers was detected in five of 20 eyes (25%) after cessation of treatment, suggesting a therapeutic effect and a need for further studies to optimize the treatment regimen.

Eric G Romanowski - One of the best experts on this subject based on the ideXlab platform.

  • antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5 New Zealand Rabbit ocular model
    Antiviral Research, 2001
    Co-Authors: Eric G Romanowski, Kathleen A Yates, Jerold Y Gordon
    Abstract:

    Adenoviral ocular infections are the most common external ocular infections world wide and there is no approved treatment. Topical cidofovir has been shown to be effective in vitro, in animal models and in case studies for the treatment of adenoviral ocular infections. Prophylaxis to prevent transmission within households and to reduce community epidemics remains an important public health goal. The current study examined whether antiviral prophylaxis with cidofovir, twice daily dosing, would restrict viral replication following a large challenge inoculum of adenovirus type 5 (Ad5) in the New Zealand white Rabbit ocular model. The results showed that antiviral prophylaxis with 1 and 0.5% cidofovir significantly reduced mean daily Ad5 ocular titers (days 0-5), the number of Ad5 positive cultures/total (days 1-14), serial Ad5 positive cultures/total (days 1, 2, 3, 4, 5, 7), and the number of eyes with Ad5 replication beyond day 0 (1% cidofovir only). Antiviral prophylaxis appears to be an effective strategy to reduce and restrict adenovirus replication experimentally.

  • efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand Rabbit ocular model
    Investigative Ophthalmology & Visual Science, 2000
    Co-Authors: Eric G Romanowski, Y J Gordon
    Abstract:

    (66%); P 5 0.000002], Ad5 [84/160 (53%) versus 131/152 (86%); P , 0.000001], and Ad6 [36/128 (28%) versus 82/128 (64%); P , 0.000001]: and reduced the duration of Ad shedding for Ad1 (4.9 6 1.9 versus 9.3 6 3.3 days; P , 0.00007), Ad5 (6.4 6 2.8 versus 11.5 6 2.3 days; P , 0.0001), and Ad6 (4.4 6 2.1 versus 8.4 6 2.5 days; P , 0.00004). CONCLUSIONS. Topical 0.5% cidofovir twice daily for 7 days demonstrated significant antiviral activity against multiple adenoviral serotypes (Ad1, Ad5, and Ad6) in the New Zealand Rabbit ocular model. These in vivo data expand in vitro studies indicating the efficacy of cidofovir against different adenovirus serotypes and support its use in clinical trials. (Invest Ophthalmol Vis Sci. 2000;41: 460 ‐ 463)

  • topical corticosteroids reverse the antiviral effect of topical cidofovir in the ad5 inoculated New Zealand Rabbit ocular model
    Investigative Ophthalmology & Visual Science, 1997
    Co-Authors: Eric G Romanowski, T Araullocruz, Y J Gordon
    Abstract:

    Purpose. To determine how the addition of topical corticosteroids would affect the anti-adenoviral inhibitory effect of topical cidofovir (S-HPMPC) in the Ad5 New Zealand (Ad5/NZ) Rabbit ocular model. Methods. In a series of experiments (two-eye design), Ad5-inoculated/NZ Rabbits (10 6 pfu/eye) were treated with 1 of 3 treatment regimens. Group I was administered 1% cidofovir (CDV) twice a day for 3 days plus comfort tears four times a day for 14 days. Group 2 was administered 1% CDV twice a day for 3 days plus 1% Pred Forte four times a day for 14 days. Group 3 was administered vehicle twice a day for 3 days plus comfort tears four times a day for 14 days and served as the control. All eyes were evaluated for 21 days for serial eye titers, Ad5 positive eyes, and duration of Ad5 shedding. Results. Compared to control eyes in the Ad5/NZ Rabbit ocular model, CDV alone demonstrated a significant antiviral inhibitory effect: reduced mean Ad5 eye titer during the early phase of infection (days 3 to 7), fewer Ad5-positive eyes during the early and late (days 9 to 21) phases of infection, and shortened duration of shedding. However, concomitant treatment with both Pred Forte and CDV significantly reversed the antiviral inhibitory activity of CDV: increased mean Ad5 eye titer, increased Ad5-positive eyes (early and late phases) and prolonged duration of shedding. Conclusions. These experimental data further support the clinical development of cidofovir as a topical antiviral agent, but they' do not support a treatment regimen that includes a combination of topical corticosteroids and topical cidofovir as a desirable strategy for the treatment of symptomatic adenoviral ocular infection.

  • hpmpc a broad spectrum topical antiviral agent inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand Rabbit ocular model
    Cornea, 1994
    Co-Authors: Y J Gordon, Eric G Romanowski, T Araullocruz
    Abstract:

    Previously, we demonstrated that HPMPC, a New, broad-spectrum antiviral agent, inhibited adenovirus type 5 in the New Zealand (NZ) Rabbit ocular model (Cornea 1992; 11:529-33). Historically, no antiviral agent has been demonstrated to be effective against both herpes simplex virus type 1 (HSV-1) and adenovirus eye infections in an experimental animal model. In this study, we compared topical 0.2% HPMPC to 1% trifluridine and vehicle control in the NZ Rabbit HSV-1 keratitis model. Using a double-masked, two-eye design, NZ Rabbits were inoculated in both eyes with HSV-1 W strain (10(5) pfu/eye), and dendritic keratitis and HSV-1 ocular titers were measured serially. Compared with the control group, both topical 0.2% HPMPC and 1% trifluridine significantly reduced healing time of HSV-1 dendritic keratitis, lowered HSV-1 ocular titers on days 3 through 11, and shortened duration of HSV-1 shedding in the tear film. For all outcome parameters measured, topical 0.2% HPMPC was as effective as 1% trifluridine. A New concept of a broad-spectrum topical antiviral agent was shown to be effective against HSV-1 in an NZ Rabbit keratitis model, and further development toward clinical application appears desirable.

  • topical hpmpc inhibits adenovirus type 5 in the New Zealand Rabbit ocular replication model
    Investigative Ophthalmology & Visual Science, 1994
    Co-Authors: Y J Gordon, Eric G Romanowski, T Araullocruz
    Abstract:

    Purpose. To evaluate the antiviral inhibitory activity of HPMPC against ocular adenoviral serotypes in vitro and to determine the therapeutic efficacy and ocular toxicity of treatment with topical HPMPC on established adenovirus type 5 (AD5) McEwen infection in the New Zealand (NZ) Rabbit ocular replication model. Methods. The 50% inhibitory dose (ID50) of HPMPC was determined for various clinical isolates of AD5 and AD8 by plaque assay in A549 cells. In vivo inhibitory effects were measured by serial ocular titers and duration of viral shedding in the AD5-NZ Rabbit ocular model. Local ocular toxicity was evaluated by external and slit lamp examination for blepharitis, conjunctivitis, keratitis, and iritis. Results. The mean IDS() for seven isolates of AD8 was 0.47 (range, 0.02 //g/ml to 0.82 /ig/ml), and the mean IDS0 for seven isolates of AD5 was 1.03 (range, 0.15 ^g/ml to 2.80 /^g/ml). In a series of in vivo experiments, topical administration of HPMPC for as long as 10 days (total dose, >2.8 mg) significantly reduced both AD5 ocular titers and the number of days of viral shedding compared to that for vehicle-treated control eyes. Local ocular toxicity was not clinically significant at a total dose of <10 mg administered for as long as 10 days. Conclusions. HPMPC, a broad-spectrum, long-acting nucleoside monophosphate analog, is a promising candidate for the treatment of epidemic keratoconjunctivitis infections. Further studies to ensure safety and efficacy in humans are warranted. Invest Ophthalmol Vis Sci. 1994;35:4135-4143.

Jianda Zhou - One of the best experts on this subject based on the ideXlab platform.

  • auricle shaping using 3d printing and autologous diced cartilage
    Laryngoscope, 2019
    Co-Authors: Junlin Liao, Jiaqin Xu, Qingfeng Li, Aijun Wang, Bin He, Jia Chen, Li Qian, Yong Chen, Jianda Zhou
    Abstract:

    Author(s): Liao, Junlin; Chen, Yong; Chen, Jia; He, Bin; Qian, Li; Xu, Jiaqin; Wang, Aijun; Li, Qingfeng; Xie, Hongju; Zhou, Jianda | Abstract: OBJECTIVE:To reconstruct the auricle using a porous, hollow, three-dimensional (3D)-printed mold and autologous diced cartilage mixed with platelet-rich plasma (PRP). METHODS:Materialise Magics v20.03 was used to design a 3D, porous, hollow auricle mold. Ten molds were printed by selective laser sintering with polyamide. Cartilage grafts were harvested from one ear of a New Zealand Rabbit, and PRP was prepared using 10 mL of auricular blood from the same animal. Ear cartilage was diced into 0.5- to 2.0-mm pieces, weighed, mixed with PRP, and then placed inside the hollow mold. Composite grafts were then implanted into the backs of respective Rabbits (n = 10) for 4 months. The shape and composition of the diced cartilage were assessed histologically, and biomechanical testing was used to determine stiffness. RESULTS:The 3D-printed auricle molds were 0.6-mm thick and showed connectivity between the internal and external surfaces, with round pores of 0.1 to 0.3 cm. After 4 months, the diced cartilage pieces had fused into an auricular shape with high fidelity to the anthropotomy. The weight of the diced cartilage was 5.157 ± 0.230 g (P g 0.05, compared with preoperative). Histological staining showed high chondrocyte viability and the production of collagen II, glycosaminoglycans, and other cartilaginous matrix components. In unrestricted compression tests, auricle stiffness was 0.158 ± 0.187 N/mm, similar to that in humans. CONCLUSION:Auricle grafts were constructed successfully through packing a 3D-printed, porous, hollow auricle mold with diced cartilage mixed with PRP. The auricle cartilage contained viable chondrocytes, appropriate extracellular matrix components, and good mechanical properties. LEVELS OF EVIDENCE:NA. Laryngoscope, 129:2467-2474, 2019.

  • Auricle shaping using 3D printing and autologous diced cartilage
    Laryngoscope, 2019
    Co-Authors: Junlin Liao, Jiaqin Xu, Hongju Xie, Qingfeng Li, Aijun Wang, Bin He, Jia Chen, Li Qian, Yong Chen, Jianda Zhou
    Abstract:

    OBJECTIVE: To reconstruct the auricle using a porous, hollow, three-dimensional (3D)-printed mold and autologous diced cartilage mixed with platelet-rich plasma (PRP). METHODS: Materialise Magics v20.03 was used to design a 3D, porous, hollow auricle mold. Ten molds were printed by selective laser sintering with polyamide. Cartilage grafts were harvested from one ear of a New Zealand Rabbit, and PRP was prepared using 10 mL of auricular blood from the same animal. Ear cartilage was diced into 0.5- to 2.0-mm pieces, weighed, mixed with PRP, and then placed inside the hollow mold. Composite grafts were then implanted into the backs of respective Rabbits (n = 10) for 4 months. The shape and composition of the diced cartilage were assessed histologically, and biomechanical testing was used to determine stiffness. RESULTS: The 3D-printed auricle molds were 0.6-mm thick and showed connectivity between the internal and external surfaces, with round pores of 0.1 to 0.3 cm. After 4 months, the diced cartilage pieces had fused into an auricular shape with high fidelity to the anthropotomy. The weight of the diced cartilage was 5.157 +/- 0.230 g (P > 0.05, compared with preoperative). Histological staining showed high chondrocyte viability and the production of collagen II, glycosaminoglycans, and other cartilaginous matrix components. In unrestricted compression tests, auricle stiffness was 0.158 +/- 0.187 N/mm, similar to that in humans. CONCLUSION: Auricle grafts were constructed successfully through packing a 3D-printed, porous, hollow auricle mold with diced cartilage mixed with PRP. The auricle cartilage contained viable chondrocytes, appropriate extracellular matrix components, and good mechanical properties. LEVELS OF EVIDENCE: NA. Laryngoscope, 2019.

Junlin Liao - One of the best experts on this subject based on the ideXlab platform.

  • auricle shaping using 3d printing and autologous diced cartilage
    Laryngoscope, 2019
    Co-Authors: Junlin Liao, Jiaqin Xu, Qingfeng Li, Aijun Wang, Bin He, Jia Chen, Li Qian, Yong Chen, Jianda Zhou
    Abstract:

    Author(s): Liao, Junlin; Chen, Yong; Chen, Jia; He, Bin; Qian, Li; Xu, Jiaqin; Wang, Aijun; Li, Qingfeng; Xie, Hongju; Zhou, Jianda | Abstract: OBJECTIVE:To reconstruct the auricle using a porous, hollow, three-dimensional (3D)-printed mold and autologous diced cartilage mixed with platelet-rich plasma (PRP). METHODS:Materialise Magics v20.03 was used to design a 3D, porous, hollow auricle mold. Ten molds were printed by selective laser sintering with polyamide. Cartilage grafts were harvested from one ear of a New Zealand Rabbit, and PRP was prepared using 10 mL of auricular blood from the same animal. Ear cartilage was diced into 0.5- to 2.0-mm pieces, weighed, mixed with PRP, and then placed inside the hollow mold. Composite grafts were then implanted into the backs of respective Rabbits (n = 10) for 4 months. The shape and composition of the diced cartilage were assessed histologically, and biomechanical testing was used to determine stiffness. RESULTS:The 3D-printed auricle molds were 0.6-mm thick and showed connectivity between the internal and external surfaces, with round pores of 0.1 to 0.3 cm. After 4 months, the diced cartilage pieces had fused into an auricular shape with high fidelity to the anthropotomy. The weight of the diced cartilage was 5.157 ± 0.230 g (P g 0.05, compared with preoperative). Histological staining showed high chondrocyte viability and the production of collagen II, glycosaminoglycans, and other cartilaginous matrix components. In unrestricted compression tests, auricle stiffness was 0.158 ± 0.187 N/mm, similar to that in humans. CONCLUSION:Auricle grafts were constructed successfully through packing a 3D-printed, porous, hollow auricle mold with diced cartilage mixed with PRP. The auricle cartilage contained viable chondrocytes, appropriate extracellular matrix components, and good mechanical properties. LEVELS OF EVIDENCE:NA. Laryngoscope, 129:2467-2474, 2019.

  • Auricle shaping using 3D printing and autologous diced cartilage
    Laryngoscope, 2019
    Co-Authors: Junlin Liao, Jiaqin Xu, Hongju Xie, Qingfeng Li, Aijun Wang, Bin He, Jia Chen, Li Qian, Yong Chen, Jianda Zhou
    Abstract:

    OBJECTIVE: To reconstruct the auricle using a porous, hollow, three-dimensional (3D)-printed mold and autologous diced cartilage mixed with platelet-rich plasma (PRP). METHODS: Materialise Magics v20.03 was used to design a 3D, porous, hollow auricle mold. Ten molds were printed by selective laser sintering with polyamide. Cartilage grafts were harvested from one ear of a New Zealand Rabbit, and PRP was prepared using 10 mL of auricular blood from the same animal. Ear cartilage was diced into 0.5- to 2.0-mm pieces, weighed, mixed with PRP, and then placed inside the hollow mold. Composite grafts were then implanted into the backs of respective Rabbits (n = 10) for 4 months. The shape and composition of the diced cartilage were assessed histologically, and biomechanical testing was used to determine stiffness. RESULTS: The 3D-printed auricle molds were 0.6-mm thick and showed connectivity between the internal and external surfaces, with round pores of 0.1 to 0.3 cm. After 4 months, the diced cartilage pieces had fused into an auricular shape with high fidelity to the anthropotomy. The weight of the diced cartilage was 5.157 +/- 0.230 g (P > 0.05, compared with preoperative). Histological staining showed high chondrocyte viability and the production of collagen II, glycosaminoglycans, and other cartilaginous matrix components. In unrestricted compression tests, auricle stiffness was 0.158 +/- 0.187 N/mm, similar to that in humans. CONCLUSION: Auricle grafts were constructed successfully through packing a 3D-printed, porous, hollow auricle mold with diced cartilage mixed with PRP. The auricle cartilage contained viable chondrocytes, appropriate extracellular matrix components, and good mechanical properties. LEVELS OF EVIDENCE: NA. Laryngoscope, 2019.